Skip to content
BIO Events
BIO Events A few more things from #BIOCEO24… The Biotechnology Innovation Organization (BIO) 2024 CEO and Investor Conference (a.k.a. #BIOCEO24) took place February 26-27 […]
Search Results for: PBMs
Homepage
New report highlights vaccine innovation, need for investment A new report is not only a ringing endorsement of vaccine innovation but also a call
PBM Transparency Act now heads to full Senate
The Senate Commerce Committee approved legislation yesterday which prohibits pharmacy benefit managers (PBMs) from pocketing the rebates they collect from drug makers. The bill
PBM Transparency Act now heads to full Senate Read More »
Fund tracing shows that a reform of 340B is long overdue
Questions regarding the significant profits made by the 340B Drug Pricing Program were raised before the United States Senate Committee on Health, Education, Labor,
Fund tracing shows that a reform of 340B is long overdue Read More »
Senate hearing considers Pharmacy Benefit Manager Transparency Act of 2023
Pharmacy benefit managers, or PBMs, could be required to be more transparent about their business practices if Congress passes S. 127, the Pharmacy Benefit
Senate hearing considers Pharmacy Benefit Manager Transparency Act of 2023 Read More »
We’re already seeing the impact of drug price controls, say biotech CEOs
The Inflation Reduction Act’s drug price controls have been a hot topic during the BIO CEO and Investor Conference—and one that has hampered an
We’re already seeing the impact of drug price controls, say biotech CEOs Read More »
Are SPACs dead? – and other questions about the biotech market outlook
The narrative is that it’s a bad market for biotech, but CEOs and investors told a packed house at the 2023 BIO CEO and
Are SPACs dead? – and other questions about the biotech market outlook Read More »
What BIO’s watching on health care and agriculture policy in 2023
With the 118th Congress picking up steam, the Biotechnology Innovation Organization’s (BIO) Federal Government Relations team shared what to expect in health care and
What BIO’s watching on health care and agriculture policy in 2023 Read More »
Patent systems for drugs matter – here’s why
The U.S. Patent and Trademark Office (USPTO) and the U.S. Food and Drug Administration (FDA) convened a joint session on drug patent systems yesterday.
Patent systems for drugs matter – here’s why Read More »
To ensure access for all, healthcare payment models need innovation
Paying for healthcare in the United States has been a challenging and controversial issue for years. In a landscape managed by private insurers, Medicaid,
To ensure access for all, healthcare payment models need innovation Read More »